L-type calcium channels as drug targets in CNS disorders

Channels

Volumn 10, Issue 1, 2016, Pages 7-13

  Ortner, Nadine J ^a   Striessnig, Jörg ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cav1.2; Cav1.3; Drug selectivity; L type calcium channels; Neuropsychiatric disorders; Pharmacology; Voltage gated calcium channels

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CP8 (1 (3 CHLOROPHENETHYL) 3 CYCLOPENTYLPYRIMIDINE 2,4,6 (1H,3H,5H) TRIONE; DILTIAZEM; ISRADIPINE; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; UNCLASSIFIED DRUG; VERAPAMIL;

AUTISM; BRAIN DISEASE; DRUG SELECTIVITY; DRUG TARGETING; FEBRILE CONVULSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; METABOLIC INHIBITION; NEUROPSYCHIATRIC DISORDER; NONHUMAN; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS;

EID: 84963999511     PISSN: 19336950     EISSN: 19336969     Source Type: Journal    
DOI: 10.1080/19336950.2015.1048936     Document Type: Review

References (75)

1. Hell JW, Westenbroek RE, Warner C, Ahlijanian MK, Prystay W, Gilbert MM, Snutch TP, Catterall WA. Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel a 1 subunits. J Cell Biol 1993; 123:949-62; PMID:8227151; http://dx.doi.org/10.1083/jcb.123.4.949
2. 2+ channels is dependent on a Shank-binding domain. J Neurosci 2005; 25:1050-62; PMID:15689540; http://dx.doi.org/10.1523/JNEUROSCI.3327-04.2005
3. Dragicevic E, Poetschke C, Duda J, Schlaudraff F, Lammel S, Schiemann J, Fauler M, Hetzel A, Watanabe M, Lujan R, et al. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Brain 2014; 137:2287-302; PMID:24934288; http://dx.doi.org/10.1093/brain/awu131
4. 2+ channels in cardiac pacemaker activity. Proc Natl Acad Sci U S A 2003; 100:5543-8; PMID:12700358; http://dx.doi.org/10.1073/pnas.0935295100
5. Marcantoni A, Vandael DH, Mahapatra S, Carabelli V, Sinnegger-Brauns MJ, Striessnig J, Carbone E. Loss of Cav1.3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells. J Neurosci 2010; 30:491-504; PMID:20071512; http://dx.doi.org/10.1523/JNEUROSCI.4961-09.2010
6. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005; 57:411-25; PMID:16382099; http://dx.doi.org/10.1124/pr.57.4.5
7. Striessnig J, Pinggera A, Kaur G, Bock G, Tuluc P. Ltype Ca channels in heart and brain. Wiley Interdiscip Rev Membr Transp Signal 2014; 3:15-38.
8. 2+ channels. J Clin Invest 2004; 113:1430-9; PMID:15146240; http://dx.doi.org/10.1172/JCI200420208
9. Moosmang S, Schulla V, Welling A, Feil R, Feil S, Wegener JW, Hofmann F, Klugbauer N. Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO J 2003; 22:6027-34; PMID:14609949; http://dx.doi.org/10.1093/emboj/cdg583
10. 2+. Am J Physiol Heart Circ Physiol 2007; 292:H415-25; PMID:16980345; http://dx. doi.org/10.1152/ajpheart.01214.2005
11. 2+ channel a 1C (CaV1.2) to synaptic and extrasynaptic compartments in hippocampal neurons. Eur J Neurosci 2004; 19:2109-22; PMID:15090038; http://dx.doi.org/10.1111/j.0953-816X.2004.03272.x
12. Ma H, Cohen S, Li B, Tsien RW. Exploring the dominant role of Cav1 channels in signaling to the nucleus. Biosci Rep 2012; 33(1):97-101
13. Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci 1997; 61:2083-90; PMID:9395249; http://dx.doi. org/10.1016/S0024-3205(97)00881-3
14. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, et al. Cerebral arterial spasm-a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983; 308:619-24; PMID:6338383; http://dx.doi.org/10.1056/NEJM198303173081103
15. 2+ channels: a single molecular switch for long-term potentiation/long-term depression-like plasticity and activity-dependent metaplasticity in humans. J Neurosci 2010; 30:6197-204; PMID:20445045; http://dx.doi.org/10.1523/JNEUROSCI.4673-09.2010
16. 2+ channels activating at negative voltages. J Biol Chem 2001; 276:22100-6; PMID:11285265; http://dx.doi.org/10.1074/jbc. M101469200
17. Xu W, Lipscombe D. Neuronal Cav1.3a1 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J Neurosci 2001; 21:5944-51; PMID:11487617
18. Liao P, Yu D, Li G, Yong TF, Soon JL, Chua YL, Soong TW. A smooth muscle Cav1.2 calcium channel splice variant underlies hyperpolarized window current and enhanced state-dependent inhibition by nifedipine. J Biol Chem 2007; 282:35133-42; PMID:17916557; http://dx.doi.org/10.1074/jbc.M705478200
19. 2+ channels. Circ Res 1997; 81:526-32; PMID:9314833; http://dx.doi.org/10.1161/01. RES.81.4.526
20. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 1977; 69:497-515; PMID:300786; http://dx. doi.org/10.1085/jgp.69.4.497
21. Helton TD, Xu W, Lipscombe D. Neuronal L-type calcium channels open quickly and are inhibited slowly. J Neurosci 2005; 25:10247-51; PMID:16267232; http://dx.doi.org/10.1523/JNEUROSCI.1089-05.2005
22. Park JH, Park YS, Rhim SY, Jhee OH, Kim SH, Yang SC, Lee MH, Shaw LM, Kang JS. Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:59-64; PMID:19041284; http://dx.doi.org/10.1016/j. jchromb.2008.11.021
23. Waltereit R, Mannhardt S, Nescholta S, Maser-Gluth C, Bartsch D. Selective and protracted effect of nifedipine on fear memory extinction correlates with induced stress response. Learn Mem 2008; 15:348-56; PMID:18441293; http://dx.doi.org/10.1101/lm.808608
24. McKinney BC, Sze W, White JA, Murphy GG. L-type voltage-gated calcium channels in conditioned fear: a genetic and pharmacological analysis. Learn Mem 2008; 15:326-34; PMID:18441291; http://dx.doi.org/10.1101/lm.893808
25. 2+ channel isoforms in the extinction of conditioned fear. Learn Mem 2008; 15:378-86; PMID:18441296; http://dx. doi.org/10.1101/lm.886208
26. 2+ channels modulate depression-like behaviour in mice independent of deaf phenotype. Int J Neuropsychopharmacol 2010; 13:499-513; PMID:19664321; http://dx.doi. org/10.1017/S1461145709990368
27. 2+ channels. J Neurochem 2006; 99:1197-206; PMID:17026527; http://dx.doi.org/10.1111/j.1471-4159.2006.04186.x
28. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ. 'Rejuvenation' protects neurons in mouse models of Parkinson disease. Nature 2007; 447:1081-6; PMID:17558391; http://dx.doi.org/10.1038/nature05865
29. Guzman JN, Sanchez-Padilla J, Chan CS, Surmeier DJ. Robust pacemaking in substantia nigra dopaminergic neurons. J Neurosci 2009; 29:11011-9; PMID:19726659; http://dx.doi.org/10.1523/JNEUROSCI.2519-09.2009
30. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, Surmeier DJ. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010; 468:696-700; PMID:21068725; http://dx.doi.org/10.1038/nature09536
31. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA. The origins of oxidant stress in Parkinson disease and therapeutic strategies. Antioxid Redox Signal 2011; 14:1289-301; PMID:20712409; http://dx.doi.org/10.1089/ars.2010.3521
32. Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015; 372:1375-6; PMID:25830435
33. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008; 70:1438-44; PMID:18256367; http://dx.doi.org/10.1212/01.wnl.0000303818.38960.44
34. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 2010; 67:600-6; PMID:20437557
35. Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS. Antihypertensive agents and risk of Parkinson disease: a nationwide cohort study. PLoS One 2014; 9: e98961
36. Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson disease. Am J Epidemiol 2012; 175:627-35; PMID:22387374; http://dx.doi.org/10.1093/aje/kwr362
37. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson disease. Neurobiol Dis 2011; 43:364-71; PMID:21515375; http://dx.doi.org/10.1016/j.nbd.2011.04.007
38. Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. One-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996; 741:185-96; PMID:9001722; http://dx.doi.org/10.1016/S0006-8993(96)00917-1
39. 2+ channels. Cell 2000; 102:89-97; PMID:10929716; http://dx.doi.org/10.1016/S0092-8674(00)00013-1
40. Radzicki D, Yau HJ, Pollema-Mays SL, Mlsna L, Cho K, Koh S, Martina M. Temperature-sensitive Cav1.2 calcium channels support intrinsic firing of pyramidal neurons and provide a target for the treatment of febrile seizures. J Neurosci 2013; 33:9920-31.; PMID:23761887; http://dx.doi.org/10.1523/JNEUROSCI.5482-12.2013
41. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, Schwartz PJ, Joseph RM, Condouris K, et al. Cav1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119:19-31; PMID:15454078; http://dx.doi.org/10.1016/j. cell.2004.09.011
42. Barrett CF, Tsien RW. The Timothy syndrome mutation differentially affects voltage-and calcium-dependent inactivation of Cav1.2 L-type calcium channels. Proc Natl Acad Sci U S A 2008; 105:2157-62; PMID:18250309; http://dx.doi.org/10.1073/pnas.0710501105
43. Marks ML, Trippel DL, Keating MT. Long QT syndrome associated with syndactyly identified in females. Am J Cardiol 1995; 76:744-5; PMID:7572644; http://dx.doi.org/10.1016/S0002-9149(99)80216-1
44. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC, Keating MT. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A 2005; 102:8089-96; discussion 6-8; PMID:15863612; http://dx.doi.org/10.1073/pnas.0502506102
45. Gillis J, Burashnikov E, Antzelevitch C, Blaser S, Gross G, Turner L, Babul-Hirji R, ChitayatD. Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am J Med Genet A 2012; 158A:182-7; PMID:22106044; http://dx. doi.org/10.1002/ajmg.a.34355
46. Dao DT, Mahon PB, Cai X, Kovacsics CE, Blackwell RA, Arad M, Shi J, Zandi PP, O'Donnell P, Bipolar Genome Study C, et al. Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry 2010; 68:801-10; PMID:20723887; http://dx.doi.org/10.1016/j.biopsych.2010.06.019
47. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013; 45:1150-9; PMID:23974872; http://dx.doi.org/10.1038/ng.2742
48. Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381:1371-9; PMID:23453885; http://dx. doi.org/10.1016/S0140-6736(12)62129-1
49. Yoshimizu T, Pan JQ, Mungenast AE, Madison JM, Su S, Ketterman J, Ongur D, McPhie D, Cohen B, Perlis R, et al. Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. Mol Psychiatry 2015; 20:162-9; PMID:25403839; http://dx.doi.org/10.1038/mp.2014.143
50. Post RM, Frye MA, Denicoff KD, Leverich GS, Dunn RT, Osuch EA, Speer AM, Obrocea G, Jajodia K. Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review. Bipolar Disord 2000; 2:305-15; PMID:11252642; http://dx.doi.org/10.1034/j.1399-5618.2000.020403.x
51. Hollister LE, Trevino ES. Calcium channel blockers in psychiatric disorders: a review of the literature. Can J Psychiatry 1999; 44:658-64; PMID:10500866
52. Lencz T, Malhotra AK. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol Psychiatry 2015; 20:820-6; PMID:25869805
53. Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45:1055-60; PMID:23913004; http://dx.doi.org/10.1038/ng.2716
54. Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45:1050-4; PMID:23913001; http://dx. doi.org/10.1038/ng.2695
55. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee C, Smith JD, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012; 485:246-50; PMID:22495309; http://dx.doi.org/10.1038/nature10989
56. Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, Yamrom B, Lee YH, Narzisi G, Leotta A, et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012; 74:285-99; PMID:22542183; http://dx.doi.org/10.1016/j. neuron.2012.04.009
57. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, Kou Y, Liu L, Fromer M, Walker S, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014; 515:209-15; PMID:25363760; http://dx.doi.org/10.1038/nature13772
58. Pinggera A, Lieb A, Benedetti B, Lampert M, Monteleone S, Liedl KR, Tuluc P, Striessnig J. CACNA1D De Novo Mutations in Autism Spectrum Disorders Activate Cav1.3 L-Type Calcium Channels. Biol Psychiatry 2015; 77:816-22; PMID:25620733; http://dx. doi.org/10.1016/j.biopsych.2014.11.020
59. 2+ channels. Trends Pharmacol Sci 1998; 19:108-15; PMID:9584627; http://dx.doi.org/10.1016/S0165-6147(98)01171-7
60. Kang S, Cooper G, Dunne SF, Dusel B, Luan CH, Surmeier DJ, Silverman RB. Cav1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson disease. Nat Commun 2012; 3:1146; PMID:23093183; http://dx.doi.org/10.1038/ncomms2149
61. Kang S, Cooper G, Dunne SF, Luan CH, Surmeier DJ, Silverman RB. Structure-activity relationship of N,N'- disubstituted pyrimidinetriones as Cav1.3 calcium channel-selective antagonists for Parkinson disease. J Med Chem 2013; 56:4786-97; PMID:23651412; http://dx.doi.org/10.1021/jm4005048
62. 42-selective inhibition by compound 8 is b-subunit dependent. Nat Commun 2014; 5:4481; PMID:25057870
63. 2+ channel activators. Nat Commun 2014; 5:3897; PMID:24941892; http://dx.doi.org/10.1038/ncomms4897
64. Sanchez-Padilla J, Guzman JN, Ilijic E, Kondapalli J, Galtieri DJ, Yang B, Schieber S, Oertel W, Wokosin D, Schumacker PT, et al. Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat Neurosci 2014; 17(6):832-40; PMID:24816140
65. Lieb A, Scharinger A, Sartori S, Sinnegger-Brauns MJ, Striessnig J. Structural determinants of Cav1.3 L-type calcium channel gating. Channels (Austin) 2012; 6: 197-205; PMID:22760075; http://dx.doi.org/10.4161/chan.21002
66. Tang ZZ, Hong X, Wang J, Soong TW. Signature combinatorial splicing profiles of rat cardiac-and smooth-muscle Cav1.2 channels with distinct biophysical properties. Cell Calcium 2007; 41:417-28; PMID:16979758; http://dx.doi.org/10.1016/j. ceca.2006.08.002
67. 2+ channel b-subunits: structural insights AID our understanding. Trends Pharmacol Sci 2004; 25:626-32; PMID:15530640; http://dx.doi.org/10.1016/j. tips.2004.10.008
68. Hulme JT, Yarov-Yarovoy V, Lin TW, Scheuer T, Catterall WA. Autoinhibitory control of the Cav1.2 channel by its proteolytically processed distal C-terminal domain. J Physiol 2006; 576:87-102; PMID:16809371; http://dx.doi.org/10.1113/jphysiol.2006.111799
69. McDonough SI, Mori Y, Bean BP. FPL 64176 modification of Cav1.2 L-type calcium channels: dissociation of effects on ionic current and gating current. Biophys J 2005; 88:211-23; PMID:15501945; http://dx.doi.org/10.1529/biophysj.104.051714
70. Marzian S, Stansfeld PJ, Rapedius M, Rinne S, Nematian-Ardestani E, Abbruzzese JL, Steinmeyer K, Sansom MS, Sanguinetti MC, Baukrowitz T, et al. Side pockets provide the basis for a new mechanism of Kv channelspecific inhibition. Nat Chem Biol 2013; 9:507-13; PMID:23728494; http://dx.doi.org/10.1038/nchembio.1271
71. 2+-dependent gating of Cav1.3 L-type calcium channels by alternative splicing of a C-terminal regulatory domain. J Biol Chem 2008; 283:20733-44; PMID:18482979; http://dx.doi.org/10.1074/jbc.M802254200
72. Gomez-Ospina N, Tsuruta F, Barreto-Chang O, Hu L, Dolmetsch R. The C terminus of the L-type voltagegated calcium channel Cav1.2 encodes a transcription factor. Cell 2006; 127:591-606; PMID:17081980; http://dx.doi.org/10.1016/j.cell.2006.10.017
73. Schroder E, Byse M, Satin J. L-type calcium channel C terminus autoregulates transcription. Circ Res 2009; 104:1373-81; PMID:19461046; http://dx.doi.org/10.1161/CIRCRESAHA.108.191387
74. Fu Y, Westenbroek RE, Scheuer T, Catterall WA. Phosphorylation sites required for regulation of cardiac calcium channels in the fight-or-flight response. Proc Natl Acad Sci U S A 2013; 110:19621-6; PMID:24218620; http://dx.doi.org/10.1073/pnas.1319421110
75. Fu Y, Westenbroek RE, Scheuer T, Catterall WA. Basal and b-adrenergic regulation of the cardiac calcium channel Cav1.2 requires phosphorylation of serine 1700. Proc Natl Acad Sci U S A 2014; 111:16598-603; PMID:25368181; http://dx.doi.org/10.1073/pnas. 1419129111